Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes (NCT07284875)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Who can join: Review the eligibility criteria below.
Location: Kailera Clinical Site — Anniston, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (88 Sites)
Showing the first 25 of 88 sites.
- Kailera Clinical Site — Anniston, Alabama
- Kailera Clinical Site — Birmingham, Alabama
- Kailera Clinical Site — Cullman, Alabama
- Kailera Clinical Site — Sun City, Arizona
- Kailera Clinical Site — Escondido, California
- Kailera Clinical Site — Toluca Lake, California
- Kailera Clinical Site — Aurora, Colorado
- Kailera Clinical Site — Bridgeport, Connecticut
- Kailera Clinical Site — Jupiter, Florida
- Kailera Clinical Site — Lilburn, Georgia
- Kailera Clinical Site — Springfield, Illinois
- Kailera Clinical Site — Columbia, Maryland
- Kailera Clinical Site — Las Vegas, Nevada
- Kailera Clinical Site — Rochester, New York
- Kailera Clinical Site — Morehead City, North Carolina
- Kailera Clinical Site — Chickasha, Oklahoma
- Kailera Clinical Site — Mauldin, South Carolina
- Kailera Clinical Site — Chattanooga, Tennessee
- Kailera Clinical Site — Amarillo, Texas
- Kailera Clinical Site — Bellaire, Texas
- Kailera Clinical Site — DeSoto, Texas
- Kailera Clinical Site — Tomball, Texas
- Kailera Clinical Site — Salt Lake City, Utah
- Kailera Clinical Site — Danville, Virginia
- Kailera Clinical Site — San Nicolás de los Arroyos, Buenos Aires
📞 Contact the Study Coordinator
Phone: (781) 317-0291
Email: info-clinicalstudies@kailera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity
- Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools — Tampa, Florida
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity — Tucson, Arizona
- Piloting a Patient Navigator Program for Weight Loss — Philadelphia, Pennsylvania
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) — Mesa, Arizona
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects — Orlando, Florida
- Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans — Pittsburgh, Pennsylvania
Explore by condition: All Obesity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.